Neoadjuvant PD-1 Antibody Alone or Combined With Autologous Glioblastoma Stem-like Cell Antigens-primed DC Vaccines (GSC-DCV) for Patients With Recurrent Glioblastoma A Phase II, Randomized Controlled, Double Blind Clinical Trial
Latest Information Update: 01 Jul 2024
At a glance
- Drugs Camrelizumab (Primary) ; Dendritic cell vaccines
- Indications Glioblastoma
- Focus Therapeutic Use
- 04 Jun 2024 Results (n=20) assessing safety and efficacy presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 13 Aug 2021 Planned initiation date changed from 21 Jul 2021 to 20 Aug 2021.
- 20 Jul 2021 Planned initiation date (estimated date of first participant enrollement) changed from 1 Jul 2021 to 21 Jul 2021.